FDA Approves Rucaparib for Recurrent Ovarian Cancer Maintenance Therapy

The FDA has granted approval of rucaparib for maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Source: CancerNetwork - April 11, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers SiteTerms/www.cannabissciencetech.com/News Ovarian Cancer Source Type: news